Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 348 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Coronary Artery Syndrome
Interventions
intensive LDL-lowering therapy, standard statin monotherapy
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
31 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Denver, Colorado • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Sacramento, California • Golden, Colorado • Miami, Florida + 13 more
Conditions
Dyslipidemia
Interventions
Educational content on statin side effects
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2029
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Results available

Simvastatin Therapy in Smith-Lemli-Opitz Syndrome

NCT00064792
Conditions
Smith-Lemli-Opitz Syndrome
Interventions
Simvastatin Susp., OraPlus
Drug
Lead sponsor
Forbes Porter, M.D.
NIH
Eligibility
4 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
HIV Infections, HIV Seronegativity, Lipodystrophy
Interventions
Pravastatin sodium, Simvastatin, Atorvastatin calcium, Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
10
States / cities
Stanford, California • Denver, Colorado • Baltimore, Maryland + 6 more
Conditions
HIV Infections
Interventions
Ezetimibe
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more
Conditions
Head and Neck Neoplasms, Hearing Disorder, Hyperlipidemia
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Bethesda, Maryland
Terminated Phase 1 Interventional Results available

Clinical Utility of Endothelial Dysfunction in PAD

NCT00491751
Conditions
Peripheral Arterial Disease
Interventions
atorvastatin, ascorbic acid, Placebo
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Phase 2 Interventional Results available

Simvastatin For Intracerebral Hemorrhage Study

NCT00718328
Conditions
Intracerebral Hemorrhage
Interventions
Simvastatin 80 mg, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Cardiovascular Disease, Childhood ALL, Childhood NHL
Interventions
Atorvastatin, Sugar Pill (Placebo)
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 39 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Intracerebral Hemorrhage
Interventions
Statins
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years and older
Enrollment
1,456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting Phase 4 Interventional

DESIFOR-EXPAND (MHIF)

NCT06804980
Conditions
Statin Therapy, Statin Adverse Reaction, Statin
Interventions
Rosuvastatin (Crestor), Placebo
Drug
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Dyslipidemias
Interventions
40 mg Pravastatin (Pravachol), 20 mg Simvastatin, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
20 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
La Jolla, California
Completed Not applicable Interventional Results available

Genetically Guided Statin Therapy

NCT01894230
Conditions
Hypercholesterolemia, Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction
Interventions
SLCO1B1*5 allele testing, results reported at randomization, SLCO1B1*5 allele testing, results reported at end of study, Genetic testing for SLCO1B1*5 allele
Genetic
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Travis Air Force Base, California • Durham, North Carolina
Conditions
Hip Fracture, Myocardial Ischemia, Inflammation
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
65 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
New York, New York
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of Trilipix Effects on Lipids and Arteries

NCT01025492
Conditions
Dyslipidemia
Interventions
Trilipix, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
30 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Perioperative Inflammatory Response
Interventions
Simvastatin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Healthy Volunteers, Statins, Immune Modulation
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Neoplasms
Interventions
Rosuvastatin, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Conditions
Cardiac Toxicity, Early-stage Breast Cancer
Interventions
Lipitor 40mg Tablet
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 5 more
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
Placebo, Statin, PF-04950615 (RN316), Satin
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
38
States / cities
Tustin, California • Walnut Creek, California • Clearwater, Florida + 25 more
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study

NCT05912387
Conditions
Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
Interventions
Rosuvastatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Stanford, California
Conditions
Cardiovascular Diseases, Dyslipidemia
Interventions
KIF6 genetic test
Genetic
Lead sponsor
Medco Health Solutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Franklin Lakes, New Jersey
Terminated Phase 4 Interventional Results available

The Effect of Lipitor on Aortic Stenosis

NCT00590135
Conditions
Aortic Valve Stenosis
Interventions
atorvastatin (Lipitor)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio